ערך בספרים למניה: Ovid Rx (OVID)

Ovid Therapeutics Inc. develops unique molecules to combat epilepsy, leveraging patent protection. Its financial standing depends on liquidity reserves for conducting tests, while its growth trajectory is tied to the success of medical research. The final book value per share reflects changes in the capital structure, with 1.14 representing the current metric.

Net asset analysis is used to select assets with the maximum margin of safety, as net assets form an investor's liquidation cushion after deducting all liabilities. This criterion is critically important for Ovid Therapeutics Inc. (OVID) during a period of intensive R&D expenditures on epilepsy drugs, which is clearly reflected in the reported book value per share on the GURU.Markets platform.